$AZTA

$39.08 +$1.91 (5.14%) Close

$AZTA Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Company Executives

$AZTA Management Team

Mr. Frank Casal

Independent Chairman of the Board

Age 71

Compensation $404.8K USD

Sex Male

Mr. John Marotta

President

Chief Executive Officer

Director

Age 46

Compensation $10.37M USD

Sex Male

Mr. Lawrence Lin

Chief Financial Officer

Executive Vice President

Age 48

Compensation $3.910M USD

Sex Male

Ms. Olga Pirogova

Chief Human Resources Officer

Senior Vice President

Age 51

Compensation $1.702M USD

Sex Female

Mr. Ephraim Starr

Senior Vice President

General Counsel

Corporate Secretary

Age 54

Compensation $2.482M USD

Sex Male

Dr. Ginger Zhou

Senior Vice President

General Manager - Multi-Omics

Age 49

Compensation $1.548M USD

Sex Female

Mr. Yvonne Perron

Vice President - Financial

Planning & Analysis and Investor Relations

Age -

Compensation -

Sex Male

Name / Title	Age	Compensation	Sex
Mr. Frank Casal Independent Chairman of the Board	71	$404.8K USD	Male
Mr. John Marotta President Chief Executive Officer Director	46	$10.37M USD	Male
Mr. Lawrence Lin Chief Financial Officer Executive Vice President	48	$3.910M USD	Male
Ms. Olga Pirogova Chief Human Resources Officer Senior Vice President	51	$1.702M USD	Female
Mr. Ephraim Starr Senior Vice President General Counsel Corporate Secretary	54	$2.482M USD	Male
Dr. Ginger Zhou Senior Vice President General Manager - Multi-Omics	49	$1.548M USD	Female
Mr. Yvonne Perron Vice President - Financial Planning & Analysis and Investor Relations	-	-	Male

Board of Directors

From the proxy statement filed Dec 18, 2025

Directors

serving now

Independent

9 of 10

stated in the proxy

Average tenure

2.8 years

from year joined

CEO also chairs the board

Frank E. Casal

Director	Age	On board	Independent	Committees	Other public boards	2025 pay
John P. Marotta CEO	46	2024 1 year	Not independent	Value Creation	None stated	Paid as CEO
Frank E. Casal Board chair	71	2021 4 years	Independent	Audit · Chair	None stated	$404,765
William L. Cornog	61	2024 1 year	Independent	Value Creation · Chair	Brightview Holdings Inc. (NYSE: BV)	$288,873
Robyn C. Davis	64	2013 12 years	Independent	Human Resources and Compensation · Chair	Psychemedics Corporation	$303,187
Quentin G. Koffey	48	2024 1 year	Independent	Human Resources and Compensation	Masimo Corporation (NASDAQ: MASI)	$289,498
Martin Madaus	66	2024 1 year	Independent	Nominating and Governance · Chair	Repligen Corporation (NASDAQ: RGEN)	$295,123
Alan J. Malus	66	2024 1 year	Independent	Value Creation	None stated	$286,998
Erica J. McLaughlin	49	2020 5 years	Independent	Environmental, Social and Governance · Chair	None stated	$301,373
Tina S. Nova	72	2023 2 years	Independent	Environmental, Social and Governance	Exagen, Inc. (NASDAQ: XGN)	$293,248
Dipal Doshi	50	2025 0 years	Independent	Audit	Entrada Therapeutics (NASDAQ: TRDA)	$267,623

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Dec 18, 2025 states there were none.

Read it in the proxy

Comments

Company Executives

$AZTA Management Team

Mr. Frank Casal

Mr. John Marotta

Mr. Lawrence Lin

Ms. Olga Pirogova

Mr. Ephraim Starr

Dr. Ginger Zhou

Mr. Yvonne Perron

Board of Directors

Related-party transactions

No related-party transactions disclosed